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804 The Journal of Thoracic and CardioObjective: The purpose of this study was to evaluate the results of a combined
resection of the thoracic aorta and primary lung cancer.
Methods: Sixteen patients underwent thoracic aorta resection along with a left
pneumonectomy (n  6), left upper lobectomy (n  9), or partial lung resection
(n 1), of whom 10 also received preoperative induction therapy. Cardiopulmonary
bypass was used in 10 patients, and a passive shunt between the ascending aorta and
the descending aorta was used in 4 patients.
Results: Six postoperative major complications occurred in 5 patients, including
postoperative bleeding (n  3), intraoperative bleeding (n  1), chylothorax (n 
1), and respiratory failure (n  1). The postoperative morbidity rate was 31%, and
the mortality rate was 12.5% (2/16). Furthermore, 4 patients died of systemic tumor
relapse, and 1 patient died of intrapleural recurrence. Nine patients were alive after
a median follow-up of 54 months (range, 12-199 months). The median survival time
of patients with postoperative pathologic N0 disease was 31 months, whereas it was
10 months for those with pathologic N2 or N3 disease. Five-year survivals were
70% for patients with N0 disease and 16.7% for patients with N2 or N3 disease
(P  .0070).
Conclusions: Although pulmonary resection with the involved aorta might cause
high surgical morbidity and mortality rates, encouraging long-term survivals were
obtained in patients without mediastinal nodal involvement.
Many studies have described a combined resection of the tho-racic aorta in patients with thoracic malignancies1-5 and pro-vided information regarding prognostic factors, surgical tech-niques, and early postoperative results. However, long-termbenefits have been rarely attained with an extended operation,and thus lung cancer with aortic invasion has been considered
inoperable.6-8
Preoperative induction therapy has been recommended for treatment of tumors
invading the aorta, as well as other types of T4 lung cancer, to improve surviv-
al.1,5,9,10 In addition, the hemi-clamshell approach has been proposed as a suitable
method to obtain a wide mediastinal view.1,5 We have used both as effective
methods for complete and en bloc resections of tumors and the involved aorta.
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treatment, is technically demanding, it is not more compli-
cated than resection of other types of T4 lung cancer, such
as tumors with infiltration to the trachea, carina, superior
vena cava, or vertebrae. The goal of the present study was
to determine the effect of a combined resection of primary
non–small cell lung cancer and the involved thoracic aorta
on patient outcome.
Patients and Methods
Sixteen patients (all men; age range, 30-66 years; mean age, 55
years) underwent a radical resection of primary lung cancer and
the affected aorta between 1986 and 2002 (Table 1). Histologi-
cally, the tumors consisted of adenocarcinoma (n  8), squamous
cell carcinoma (n  5), and large cell carcinoma (n  3). At the
time of initial staging, all patients were given a diagnosis of
infiltration of the aorta (clinical T4) on the basis of the findings of
chest computed tomography (CT), which were confirmed by a
clinical radiologist. All patients underwent a bone scan, abdominal
CT imaging, and magnetic resonance imaging or CT imaging of
the head to rule out distant metastasis. We did not use thoracos-
copy, mediastinoscopy, or thoracotomy for the staging of T and N
status before the surgical resection. Mediastinal lymphadenopathy
was diagnosed as clinical N2 disease without histologic confirma-
tion when the lymph node had a short diameter of greater than 1.0
cm on the CT image.
Nine patients underwent preoperative chemoradiotherapy, and
one underwent preoperative chemotherapy alone. Chemotherapy
regimens consisted of 4 different platinum-based combinations,
whereas radiation therapy was performed with an average dose of
45 Gy (range, 30-60 Gy), with the radiation field encompassing the
primary tumor, ipsilateral hilum, and mediastinum. In cases of
chemoradiotherapy, the 2 modalities were initiated concurrently.
Four patients who did not undergo preoperative treatment received
postoperative chemotherapy. Staging of the entire patient popula-
tion resulted in classification as postoperative pathologic stage IV
(n  2), IIIB (n  9), IIIA (n  1), IIB (n  2), and IB (n  1)
disease. One patient showed no viable tumor cells after surgical
intervention.
Treatment Strategies
The first 7 patients in the present series were treated on an ad hoc
basis between 1986 and 1994. Of those, 5 underwent surgical
resection as the first therapy, and 2 underwent chemoradiotherapy
with subsequent surgical resection (patients 1-7 in Table 1).
On the basis of the surgical results from these first 7 patients,
subsequent patients (ie, from 1995) underwent induction therapy
before surgical resection. Patients with tumor infiltration at the
origin of the left pulmonary artery or with left atrial invasion
alongside the pulmonary vein underwent a resection of the primary
tumor and involved aorta. Other patients were not considered for
operative management, including those with tumor infiltration over
the aorta to the trachea, distant metastasis, or local disease pro-
gression after induction therapy. One patient (patient 9) with
chronic hepatitis was treated surgically without any adjuvant ther-
apy.
The Journal of ThoraciOperative Procedures
The surgical approach used was a hemi-clamshell thoracotomy
(n  10) or posterolateral thoracotomy (n  6). Partial cardiopul-
monary bypass (CPB) between the femoral vein and femoral artery
was used in 9 patients, a temporary bypass graft from the ascend-
ing aorta to the descending aorta was used in 3 patients, and
isolated brain perfusion and deep hypothermia was used in 1
patient, whereas the remaining 3 patients did not require any
bypass technique (Table 1). The aorta was replaced with a pros-
thetic graft in 10 patients, a partial defect of the aortic wall was
closed with a prosthetic patch in 5 patients, and direct closure of a
small defect was performed in 1 patient. Seven patients underwent
reconstruction of the subclavian artery, 2 patients underwent re-
construction of the common carotid artery, and 1 patient under-
went partial vertebral resection. We attempted to avoid recycling
blood aspirated from the pleural cavity during the procedure.
All patients were informed that the operative morbidity and
mortality were high and that chemotherapy and chemoradiother-
apy were alternative treatments with lower treatment-related mor-
bidity and mortality. Written informed consent was obtained from
all 16 patients.
Major complications were defined as those that would be lethal
unless treated adequately. Survival was calculated by the Kaplan-
Meier method from the start of preoperative therapy for 10 patients
and from the time of the operation for the 6 patients who did not
undergo induction therapy. Differences among the curves were
analyzed by a log-rank test. Postoperative pathologic N and T
status were evaluated as predictors of survival.
Results
Major complications occurred in 5 patients (Table 2).Three
patients had intrapleural bleeding after the operation, and
one of those died from the complication. Another patient
had an aortic laceration just distal to the left subclavian
artery and bled to death. One patient had respiratory failure
requiring mechanical ventilation. Thus, the morbidity rate
was 31% (5/16), and the mortality rate was 12.5% (2/16).
In 5 patients who received preoperative induction ther-
apy, no histologic evidence of aortic involvement was found
after the operation. Three patients with clinical N2 disease
(patients 12, 15, and 16) and 1 patient with clinical N1
disease (patient 13) had a marked reduction in lymphade-
nopathy after induction therapy and showed no metastasis
on postoperative histologic examination. Therefore, a pos-
sible downstaging of TNM status was observed in 7 of 10
patients who underwent induction therapy (patients 3, 10-
13, 15, and 16).
Twelve (75%) patients underwent complete surgical re-
section. Postoperative adjuvant therapy was performed for 4
patients in whom complete resection could not be achieved
or who did not receive preoperative therapy. Follow-up was
completed for all patients in 12 to 199 months (mean, 43
months) after the initial treatment. Four patients died of
systemic metastasis, and 1 died of intrapleural recurrence
within 33 months of the operation. Nine patients were alive
after a median follow-up period of 54 months.
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and the 5-year survival was 48.2%. The median survival
time and 5-year survival were 31 months and 70%, respec-
tively, for the 10 patients with postoperative pathologic N0
disease and 10 months and 17%, respectively, for the 6
patients with pathologic N2 or N3 disease (P  .0070,
Table 3 and Figure 1). Pathologic T factor (P  .0539) did
not appear to have an influence on survival (Table 3).
Discussion
A malignant thoracic tumor with infiltration of the aorta
carries a poor prognosis, and thus surgical resection is
contraindicated in these cases.11 However, previous studies
TABLE 1. Patient demographics
Patient
no.
Age
(y) Histology*
Preoperative
therapy†
Postoperative
therapy
1 65 Ad - PV
2 54 La - PV
3 59 Sq MVP 50 Gy -
4 62 Ad - PV
5 64 Ad - -
6 65 Sq MVP 30 Gy -
7 48 Ad - PV
8 30 La MVP 50 Gy -
9 52 Ad - -
10 47 La MVP 40 Gy -
11 63 Sq PV  40 Gy -
12 66 Sq PV 50 Gy -
13 55 Sq CTG -
14 55 Ad MVP 40 Gy -
15 50 Ad NP 60 Gy -
16 59 Ad PT 40 Gy -
*Ad, Adenocarcinoma; La, large cell carcinoma; Sq, squamous cell carci
†MVP, Cisplatin, vindesine, and mitomycin; PV, cisplatin and vindesine; C
cisplatin and docetaxel.
‡PL, Posterolateral thoracotomy; HCS, hemiclamshell thoracotomy.
§FF, Femoro-femoral partial cardiopulmonary bypass; AA bypass, tempora
monary bypass.
Patient who died.
TABLE 2. Complications and causes of death
Complication
Pleural bleeding after
operation
3 (1*)
Aortic laceration 1*
Chylothorax 1
Respiratory failure 1
Morbidity 31% (5/16)†
Mortality 12.5% (2/16)
Cause of death
Systemic metastasis 4
Local recurrence 1
*Patient who died.
†There were 6 complications among 5 patients.have shown that long-term survival is possible after limited
806 The Journal of Thoracic and Cardiovascular Surgery ● Apriresection of the aortic adventitia along with the primary
tumor.6,9,10,12 Moreover, in 4 separate studies,1,2,5,10 7 of 20
patients who underwent resection of the involved aortic wall
with subsequent graft replacement survived for at least 3
years, and each report recommended complete resection of
the entire tumor.
Preoperative induction therapy is an effective method for
achieving complete resection of lung cancer and has been
applied extensively for treatment of stage IIIA and IIIB
disease.13,14 In those studies mediastinal lymph node status
after induction treatment showed prognostic significance for
surgical treatment.7,13,14 Those reports are consistent with
findings from the present study, which demonstrated that
survival outcome was relatively favorable for patients with
postoperative pathologic N0 disease, although outcome was
still poor for those with pathologic N2 or N3 disease; and
these results underscore the importance of accurate diagno-
sis of mediastinal lymph node involvement before surgical
treatment. On the basis of our results, we suggest the fol-
lowing operative strategy. Patients with a T4 tumor infil-
trating the aorta, as confirmed by CT imaging, and with or
without clinical N2 disease should undergo preoperative
induction therapy. When these patients show no tumor
progression after therapy, further examinations, such as
video-assisted thoracoscopy, a Chamberlain procedure, or
mediastinoscopy, are required for assessment of the para-
aortic, subaortic, or paratracheal lymph nodes before defin-
roach‡
TNM status after
the operation
Cardiopulmonary
bypass§
Survival time
(mo)
L 420 FF 12
CS 420 FF 3
CS 300 (AA bypass) 199
L 420 - 33
L 430 - 7
L 301 (AA bypass) 36
L 400 FF 101
CS 421 (AA bypass) 3
CS 220 FF 64
CS 0 FF 67
L 300 FF 54
CS 200 - 26
CS 400 FF 24
CS 400 FF 27
CS 400 FF 19
CS 400 CPB, hypothermia 12
arboplatin, paclitaxel, and gemcitabine; NP, cisplatin and vinorelbine; PT,
pass from the ascending aorta to the descending aorta; CPB, cardiopul-App
P
H
H
P
P
P
P
H
H
H
P
H
H
H
H
H
noma.
TG, c
ry byitive surgical management. When no histologic evidence of
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TSmediastinal nodal involvement is found after these exami-
nations, a radical resection of the affected aorta should be
performed.
Some surgeons prefer the use of a passive shunt between
the ascending and descending aorta to avoid extracorporeal
circulation1,2 and to maintain perfusion in the lower part of
the body. However, recent technical advances and imple-
mentation of a vortex pump with a low dose of heparin have
allowed for safe and reliable circulatory support without
renal failure, cerebral complications, or spinal cord injury.15
In the present study 10 patients underwent surgical inter-
vention with CPB without critical complications, and the
intensive care unit stay was less than 3 days for each.
Operations with CPB usually use a cell salvage system,
which washes and concentrates erythrocytes aspirated from
the surgical field for subsequent transfusion to the patient.
However, in lung cancer operations, blood in the pleural
cavity might be contaminated with tumor cells. Therefore,
although evidence is limited, we consider that blood aspi-
rated from the surgical field should not be transfused back
into the patient.
Radical en bloc resection of the tumor and invaded organ
is essential for preventing intrapleural local recurrence.16
One of our patients (patient 13), who underwent discontin-
uous resections of the lung and tumor during CPB, had local
recurrence in the chest wall pleura approximately 1 year
after the operation. We suspected that the local recurrence
was due to intrapleural tumor spread resulting from the
Figure 1. Survival of patients with T4 non–small cell lung cancer
infiltrating the thoracic aorta. Solid lines and dotted lines repre-
sent survival curves and their E bars, respectively, for patients
with postoperative pathologic N0 disease (5-year survival, 70%)
or N2 or N3 disease (5-year survival, 16.7%).discontinuous resection.
The Journal of ThoraciIn conclusion, surgical morbidity and mortality rates
were high in patients who underwent resection of the tumor
and involved aorta, although similar to those of patients
with other T4 organ involvement7,13,14 treated with preop-
erative induction therapy. The encouraging long-term sur-
vivals obtained in patients with N0 disease suggest that
radical resection is a valid intervention for selected patients
with aortic involvement of non–small cell lung cancer.
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